Gossamer Bio, Inc. [GOSS] Securities Class Action Lawsuit Update

• Case Name: Kinnamon v. Gossamer Bio, Inc.
• Case No.: 3:26-cv-02016-CAB-AHG
• Jurisdiction: United States District Court, Southern District of California
• Filed on: March 31, 2026
• Class Period: June 16, 2025 - February 20, 2026

Introduction

Gossamer Bio, Inc. (NASDAQ: GOSS) and its CEO, Faheem Hasnain, are now facing a federal securities class action that turns on a familiar biotech fault line: management confidence in a pivotal readout, followed by an alleged failure tied, according to investors, to trial-design and site-selection issues highlighted after the topline disclosure. Investors allege the company repeatedly projected confidence in the design and enrollment quality of its Phase 3 PROSERA study for seralutinib in pulmonary arterial hypertension, while failing to disclose, according to the complaint, that Latin American sites included heavily treated, lower-risk patients whose placebo performance later allegedly compressed the treatment effect below the statistical threshold.

When the topline data arrived on February 23, 2026, the primary endpoint missed the pre-specified alpha threshold. GOSS fell from $2.13 to $0.42 in a single trading day, erasing more than 80% of shareholder value.

“Most GOSS shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Backdrop and Business Context

Gossamer is a clinical-stage biopharmaceutical company developing seralutinib, including in pulmonary hypertension indications such as the PAH-focused PROSERA study discussed in the complaint, with PROSERA positioned as a registrational Phase 3 catalyst. The company’s business narrative during the class period centered on transforming from a development-stage biotech into a commercial organization, supported by partnership planning and broader franchise ambitions in pulmonary vascular disease.

That backdrop matters. In biotech securities litigation, a single Phase 3 readout can function as both valuation anchor and enterprise-defining event. Here, management described seralutinib as a potential “multi-billion-dollar opportunity,” framing PROSERA as the foundation for a broader commercial franchise. That framing amplified the market significance of every statement about enrollment quality, site geography, and endpoint confidence.

The alleged misconduct emerged from this operational setup: aggressive global enrollment, significant investment in Latin American sites, and public assurances that the selected patient population was aligned with the trial’s objectives.

Promises Made vs. Reality

The complaint points directly to management’s June 16, 2025 enrollment-completion statement, where Hasnain said the company had “focused on selecting a patient population that aligns closely with the study’s objectives and is more likely to exhibit a clinically significant benefit in 24 weeks,” adding that management “firmly believe[d]” it had accomplished that goal.

That language is the heart of the alleged misrepresentation.

Investors now allege the reality was materially different: Latin American sites contained a heavily treated and lower-risk cohort that later produced an unusually strong placebo response, compressing the treatment delta below the statistical bar.

According to the complaint, defendants omitted this acute design and site-selection risk while continuing to narrate PROSERA as operationally disciplined and scientifically robust.

The contrast is stark. Publicly, the company projected disciplined execution. According to the complaint, the enrollment mix allegedly embedded a risk that later contributed to the endpoint miss.

Timeline of Alleged Misconduct and Disclosures

The alleged timeline is unusually clean, which often strengthens a securities class action narrative.

June 16, 2025: Gossamer announces completion of enrollment and expresses confidence in patient selection and endpoint alignment.

August 5, 2025: Management says the team remains focused on executing PROSERA with “discipline and operational excellence,” while preparing commercialization plans.

November 5, 2025: Gossamer reiterates confidence and says it is progressing through the final stages of the study.

February 23, 2026: The alleged corrective disclosure emerges. PROSERA fails its primary endpoint, posting a placebo-adjusted gain of +13.3 meters with p=0.0320, above the stricter 0.025 threshold. Management attributes the miss to unusually strong placebo performance, especially in Latin America.

During the analyst call, executives described the Latin America result as “extremely disturbing” and said the team was still investigating what happened. That language now functions as a corrective disclosure bridge in the complaint’s loss causation theory.

Investor Harm and Market Reaction

The market reaction was immediate and brutal. GOSS common stock collapsed from $2.13 on February 20, 2026, to $0.42 on February 23, 2026, a one-day decline of more than 80%. The complaint ties that loss directly to the disclosure that alleged Latin America site issues and placebo dynamics undermined the Phase 3 outcome.

Analyst reaction reinforced the market’s interpretation. Wedbush downgraded the stock to Neutral and cut its target from $6 to $1, citing the primary endpoint failure and unusual placebo performance in Latin America and Asia/Middle East regions.

Oppenheimer later reduced its target from $12 to $3, characterizing the Latin America issue as a trial execution irregularity rather than a drug-effect problem.

For investors, the complaint frames this as a classic loss-causation sequence: catalyst optimism, alleged omitted execution risk, corrective disclosure, and severe repricing.

Litigation and Procedural Posture

The complaint was filed in the U.S. District Court for the Southern District of California as Kinnamon v. Gossamer Bio, Inc. et al., Case No. 3:26-cv-02016-CAB-AHG. The asserted claims include Section 10(b) of the Exchange Act, Rule 10b-5, and Section 20(a) control person liability. Defendants are Gossamer Bio, Inc. and CEO and Chairman Faheem Hasnain.

The scienter theory is direct and biotech-specific: defendants allegedly knew, or were reckless in not knowing, that the Latin American site composition and placebo dynamics created a material risk that PROSERA would miss its endpoint. The complaint repeatedly points to defendants’ access to non-public information concerning trial design, site selection, and patient risk profiles.

SEC Filings & Risk Factors

The complaint explicitly references Gossamer’s SEC filings, earnings releases, and public disclosures reviewed as part of counsel’s pre-suit investigation. The key omitted risk, as framed by investors, was not generic clinical failure risk. It was more specific: that the trial’s geographic enrollment strategy, especially in Latin America, introduced a placebo distortion risk severe enough to negate statistical success despite numerical efficacy. That distinction matters for securities fraud pleading. Generic biotech warnings about clinical uncertainty may not protect against allegations that management omitted known, concrete risks in site selection and patient composition.

The complaint also challenges any forward-looking safe harbor defense, alleging the statements lacked meaningful cautionary language tailored to the actual trial-design vulnerabilities that later materialized.

How to Join the Gossamer Bio (GOSS) Class Action

• Confirm you purchased GOSS shares during the June 16, 2025 to February 20, 2026 class period
• Review eligibility details
• Click here to check eligibility

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.